These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31312744)

  • 1. Do HCWs adequately know about meningitis and 4CMenB vaccine and recommend its use to parents? A cross sectional analysis in Campania Region, Italy.
    Ponticelli D; D'Ambrosio A; Cancellieri M; Agozzino E
    J Prev Med Hyg; 2019 Jun; 60(2):E147-E157. PubMed ID: 31312744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: a survey.
    Mameli C; Faccini M; Mazzali C; Picca M; Colella G; Duca PG; Zuccotti GV
    Hum Vaccin Immunother; 2014; 10(10):3004-10. PubMed ID: 25483638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Awareness, Attitudes, and Practices Toward Meningococcal B Vaccine among Pediatricians in Italy.
    Ferrara P; Stromillo L; Albano L
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30513993
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 5. Healthcare workers' knowledge, beliefs, and coverage regarding vaccinations in critical care units in Italy.
    Napolitano F; Bianco A; D'Alessandro A; Papadopoli R; Angelillo IF
    Vaccine; 2019 Oct; 37(46):6900-6906. PubMed ID: 31564452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal serogroup B vaccine: Knowledge and acceptability among parents in Italy.
    Morrone T; Napolitano F; Albano L; Di Giuseppe G
    Hum Vaccin Immunother; 2017 Aug; 13(8):1921-1927. PubMed ID: 28441109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal disease and vaccination: Knowledge and acceptability among adolescents in Italy.
    Pelullo CP; Napolitano F; Di Giuseppe G
    Hum Vaccin Immunother; 2018 May; 14(5):1197-1202. PubMed ID: 29452028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the risk of bacterial meningitis among healthcare workers.
    Ferraro M; Morucci L; Coppeta L; De Carolis G; Pietroiusti A; Franco E; Magrini A
    Occup Med (Lond); 2019 Apr; 69(2):113-117. PubMed ID: 30496490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
    Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
    Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
    Rappuoli R; Pizza M; Masignani V; Vadivelu K
    Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.
    Lee HJ; Choe YJ; Hong YJ; Kim KH; Park SE; Kim YK; Oh CE; Lee H; Song H; Bock H; Casula D; Bhusal C; Arora AK
    Vaccine; 2016 Feb; 34(9):1180-6. PubMed ID: 26826544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.
    Esposito S; Castellazzi L; Bosco A; Musio A; Stoddard J
    Immunotherapy; 2014; 6(4):395-408. PubMed ID: 24815780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data.
    Harcourt S; Morbey RA; Bates C; Carter H; Ladhani SN; de Lusignan S; Smith GE; Elliot AJ
    Vaccine; 2018 Jan; 36(4):565-571. PubMed ID: 29246475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006-2014.
    Stefanelli P; Fazio C; Neri A; Boros S; Renna G; Pompa MG;
    Vaccine; 2015 Jul; 33(31):3678-81. PubMed ID: 26087297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction.
    Martinelli D; Fortunato F; Cappelli MG; Cozza V; Chironna M; Prato R
    J Immunol Res; 2015; 2015():710656. PubMed ID: 26351649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission.
    Poore KD; Bauch CT
    BMC Infect Dis; 2015 Jul; 15():300. PubMed ID: 26223223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
    Flacco ME; Manzoli L; Rosso A; Marzuillo C; Bergamini M; Stefanati A; Cultrera R; Villari P; Ricciardi W; Ioannidis JPA; Contopoulos-Ioannidis DG
    Lancet Infect Dis; 2018 Apr; 18(4):461-472. PubMed ID: 29371070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
    De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
    Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023.
    Stefanizzi P; Di Lorenzo A; Martinelli A; Moscara L; Stella P; Ancona D; Tafuri S
    Vaccine; 2023 Nov; 41(48):7096-7102. PubMed ID: 37891052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.